|
||
Stoplos ONE Pregnancy |
||
It is not known if bisphosphonates cross the placenta, but fetal exposure is expected (Djokanovic 2008; Stathopoulos 2011).
Information specific to Stoplos ONE exposure during pregnancy is limited (Djokanovic 2008; Richa 2018). Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by dose and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy; however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic 2008; Green 2014; Levy 2009; Sokol 2019; Stathopoulos 2011). Because hypocalcemia has been described following in utero bisphosphonate exposure, exposed infants should be monitored for hypocalcemia after birth (Djokanovic 2008; Stathopoulos 2011).
Use is contraindicated. (AU,UK) A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. (US) Excreted into human milk: Unknown Excreted into animal milk: Unknown Comments: Stoplos ONE binds to bone long term and may be released over weeks to years.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|